Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention

Jacqueline Saw, Eric J. Topol, Steven R. Steinhubl, Danielle Brennan, Peter B. Berger, David J. Moliterno

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Patients in the Clopidogrel for the Reduction of Events During Observation trial were subgrouped according to whether they underwent index percutaneous coronary artery revascularization procedures only or this procedure plus subsequent percutaneous or surgical revascularization procedures during 1-year follow-up. The relative risk reduction in ischemic events associated with up-front and long-term clopidogrel compared with placebo was 2-fold greater in patients who required repeat revascularization procedures compared with those who did not (42.4% vs 21.7%).

Original languageEnglish
Pages (from-to)623-625
Number of pages3
JournalAmerican Journal of Cardiology
Volume94
Issue number5
DOIs
StatePublished - Sep 1 2004

Bibliographical note

Funding Information:
The CREDO trial was supported by Sanofi-Synthelabo, Inc./Bristol Myers Squibb Partnership, New York, New York.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention'. Together they form a unique fingerprint.

Cite this